Drug intelligence / Profile preview

ARK-E021

Development stage: Discontinued
Lead developer: Vyne Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

ARK-E021 is a small molecule drug that was initially developed by VYNE Pharmaceuticals Ltd. for the treatment of skin and musculoskeletal diseases, with its primary indication being acne vulgaris. The drug was formulated as a topical foam and underwent clinical trials to assess its safety and efficacy in subjects with mild to moderate acne vulgaris. Despite reaching Phase 2 clinical development, the global highest R&D status for ARK-E021 is now discontinued, meaning it is no longer being actively developed or marketed[1].

Targets

GHSR (Growth hormone secretagogue receptor)

Beyond the preview

Go deeper on ARK-E021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARK-E021.

Explore the full profile